Project Grant AID521F1500010

This five-year, $536,955 project grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research under the Cancer Detection and Diagnosis Research program. The Washington University will develop pre-treatment and recurrence biomarkers for locally advanced cervical cancer by analyzing variance in human papillomavirus genomic structures among patient tumors. Researchers will extract HPV genomic features from matched DNA and RNA sequencing data to...

Morphogenesis, Inc. was awarded a $1,200,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, to develop a low-cost topical immunotherapy formulation suitable for treating cervical cancer in low- and middle-income countries and low-resource settings in the United States. The funding supports optimization of Morphogenesis' IFX-HU2.1 plasmid DNA-based cream formulation for temperature stability using established methods and models. In vitro...

This federal Project Grant award, totaling $477,869.00, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The grant aims to develop tailored, multilevel cervical cancer interventions for ethnically diverse Black women, including African American women and Black African immigrant women. The key objectives are to: 1) identify multilevel determinants of routine cervical cancer screening and follow-up adherence among these populations,...

Federal Project Grant Award Summary The University of North Carolina at Chapel Hill received a $2,065,374 Project Grant award effective September 15, 2025, from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393). The award funds a pilot Phase IIA randomized placebo-controlled trial investigating the safety, adherence, and preliminary efficacy of adjuvant 5-fluorouracil (5FU) as an intravaginal therapy administered following thermal ablation to...

Federal Grant Award Summary The National Cancer Institute awarded Oraliva, Inc. a $400,000 Project Grant under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) effective September 1, 2025, through August 31, 2026, to develop a novel point-of-care (POC) diagnostic tool for gynecological screening in low-resource settings. Oraliva will leverage its artificial intelligence-linked cytomics-on-a-chip (ONC-INCYT) technology to create the first rapid, integrated human papillomavirus...

The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.395 - Cancer Treatment Research) to Ampedrna Biosciences LLC in the amount of $398,823 to develop a highly immunogenic mini-circular RNA (mcrRNA) therapeutic cancer vaccine for human papillomavirus (HPV)-related cancers. The goal is to create an off-the-shelf or personalized vaccine that can elicit robust and durable T cell responses to target HPV E6 and E7 antigens, which are known to drive HPV-induced cancers. The proposed...

Federal Project Grant Award Summary The National Cancer Institute awarded $544,250 to the University of Nebraska Medical Center (UNMC) under the Cancer Treatment Research program (CFDA 93.395) for a five-year project running from August 4, 2025 through July 31, 2030. The award supports research investigating the immune drivers of persistent oncogenic human papillomavirus (HPV) infections in people living with HIV (PLWH), with an initial focus on oral HPV persistence as a precursor to...

Federal Project Grant Award Summary Rice University received a $104,278 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective January 11, 2026, with completion targeted for June 30, 2026. The award supports the development of an automated multimodal, multiscale deep learning algorithm for cervical cancer screening in low- and middle-income countries (LMICs). Building on existing low-cost multimodal colposcope hardware...

Federal Grant Award Summary Wayne State University received a $155,000 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) effective May 1, 2026, through April 30, 2028. This research initiative addresses a critical gap in cervical cancer (CC) prevention by investigating multi-level predictors of diagnostic follow-up (DFU) attendance after abnormal cervical cancer screening. While the United States has made progress toward Human...

Federal Grant Award Summary The National Cancer Institute awarded a $170,409 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the University of Texas Health Science Center at Houston, with performance extending from August 1, 2025 through July 31, 2027. This research project examines Human Papillomavirus (HPV) and HPV-related cancer prevention prevalence among people experiencing homelessness in the United States using data spanning 2006-2018. The study...